ログインで組織・契約価格をご覧ください。
サイズを選択してください
この商品について
実験式(ヒル表記法):
C6H12N3PS
CAS番号:
分子量:
189.22
NACRES:
NA.85
PubChem Substance ID:
UNSPSC Code:
51102829
EC Number:
200-135-7
MDL number:
InChI key
FOCVUCIESVLUNU-UHFFFAOYSA-N
InChI
1S/C6H12N3PS/c11-10(7-1-2-7,8-3-4-8)9-5-6-9/h1-6H2
SMILES string
S=P(N1CC1)(N2CC2)N3CC3
form
solid
storage condition
(Keep container tightly closed in a dry and well-ventilated place.)
color
white
antibiotic activity spectrum
neoplastics
mode of action
DNA synthesis | interferes
storage temp.
2-8°C
Quality Level
類似した製品をお探しですか? 訪問 製品比較ガイド
関連するカテゴリー
Analysis Note
可溶性-水、クロロホルムおよびエタノール(96%)に溶けやすい
Application
多官能性アルキル化剤。
Biochem/physiol Actions
不安定な窒素-炭素基はDNAとアルキル化し、それが不可逆的なDNA損傷を引き起こします。DNA二重らせんのグアニン核酸塩基に架橋することでDNAを直接攻撃し、腫瘍増殖を停止させます。DNA鎖はほどけて分離することができないため、細胞分裂が停止します。
General description
化学構造:アジリジン
Other Notes
容器は、乾燥した換気の良い場所にしっかり密閉して保管してください。
signalword
Danger
hcodes
Hazard Classifications
Acute Tox. 2 Oral - Carc. 1B
保管分類
6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials
wgk
WGK 3
ppe
Eyeshields, Faceshields, Gloves, type P3 (EN 143) respirator cartridges
Maura Massimino et al.
Pediatric blood & cancer, 60(12), 2031-2035 (2013-07-16)
A protocol for the intensive treatment of non-cerebellar PNET (CNS-PNET) combining chemotherapy and radiotherapy was launched in 2000. Efforts were subsequently made to improve the prognosis and to de-escalate the treatment for selected patient groups. Twenty-eight consecutive patients were enrolled
J Sanz et al.
Bone marrow transplantation, 47(10), 1287-1293 (2012-02-14)
Attempts to optimize outcomes in cord blood transplantation (CBT) by using new conditioning regimens and standardization of cord blood unit selection are warranted. In all, 88 patients (18 children and 70 adults) with hematological malignancy from nine Spanish institutions underwent
Sotirios G Papageorgiou et al.
Hematological oncology, 31(1), 10-17 (2012-05-23)
Central nervous system (CNS) involvement in patients with primary mediastinal large B-cell (PMLBCL) lymphoma is a rare event, occurring in approximately 6% of patients, on the basis of the review of the literature prior to induction of Rituximab. The aim
A Fabi et al.
Annals of oncology : official journal of the European Society for Medical Oncology, 6(2), 187-189 (1995-02-01)
Vinorelbine as single-agent has achieved an overall response rate of > 20% as second-line treatment and 40%-50% as first-line treatment. The aim of this study was to evaluate the activity and toxicity of the combination of vinorelbine and thiotepa as
Michael P Fay et al.
Statistics in medicine, 31(28), 3760-3772 (2012-07-13)
We consider weighted logrank tests for interval censored data when assessment times may depend on treatment, and for each individual, we only use the two assessment times that bracket the event of interest. It is known that treating finite right
ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.
製品に関するお問い合わせはこちら(テクニカルサービス)
